Literature DB >> 31488357

Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.

Sandra Codony1, Elena Valverde1, Rosana Leiva1, José Brea2, M Isabel Loza2, Christophe Morisseau3, Bruce D Hammock3, Santiago Vázquez4.   

Abstract

Soluble epoxide hydrolase (sEH) inhibitors are potential drugs for several diseases. Adamantyl ureas are excellent sEH inhibitors but have limited metabolic stability. Herein, we report the effect of replacing the adamantane group by alternative polycyclic hydrocarbons on sEH inhibition, solubility, permeability and metabolic stability. Compounds bearing smaller or larger polycyclic hydrocarbons than adamantane yielded all good inhibition potency of the human sEH (0.4 ≤ IC50 ≤ 21.7 nM), indicating that sEH is able to accommodate inhibitors of very different size. Human liver microsomal stability of diamantane containing inhibitors is lower than that of their corresponding adamantane counterparts.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adamantane; Inhibitor; Isocyanate; Soluble epoxide hydrolase; Urea

Mesh:

Substances:

Year:  2019        PMID: 31488357      PMCID: PMC6892585          DOI: 10.1016/j.bmc.2019.115078

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  47 in total

Review 1.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Authors:  Hong C Shen; Bruce D Hammock
Journal:  J Med Chem       Date:  2012-01-17       Impact factor: 7.446

Review 2.  Soluble epoxide hydrolase inhibitors and cardiovascular diseases.

Authors:  Zhen-He Wang; Benjamin B Davis; De-Qian Jiang; Ting-Ting Zhao; Dan-Yan Xu
Journal:  Curr Vasc Pharmacol       Date:  2013-01       Impact factor: 2.719

Review 3.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

Review 4.  Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.

Authors:  Karen M Wagner; Cindy B McReynolds; William K Schmidt; Bruce D Hammock
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

5.  Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.

Authors:  In-Hae Kim; In-Hee Lee; Hisashi Nishiwaki; Bruce D Hammock; Kosuke Nishi
Journal:  Bioorg Med Chem       Date:  2014-01-03       Impact factor: 3.641

6.  Metabolism of diamantane by rat liver microsomal cytochromes P-450.

Authors:  P Hodek; P Janscák; P Anzenbacher; J Burkhard; J Janků; L Vodicka
Journal:  Xenobiotica       Date:  1988-10       Impact factor: 1.908

Review 7.  A multimodal disease modifying approach to treat neuropathic pain--inhibition of soluble epoxide hydrolase (sEH).

Authors:  Sivaram Pillarisetti; Ish Khanna
Journal:  Drug Discov Today       Date:  2015-08-08       Impact factor: 7.851

Review 8.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

9.  In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors.

Authors:  Jun-Yan Liu; Hsing-Ju Tsai; Christophe Morisseau; Jozsef Lango; Sung Hee Hwang; Takaho Watanabe; In-Hae Kim; Bruce D Hammock
Journal:  Biochem Pharmacol       Date:  2015-10-19       Impact factor: 5.858

Review 10.  The role of epoxyeicosatrienoic acids in the cardiovascular system.

Authors:  L Yang; K Mäki-Petäjä; J Cheriyan; C McEniery; I B Wilkinson
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

View more
  3 in total

1.  Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors.

Authors:  Vladimir Burmistrov; Christophe Morisseau; Dmitry Karlov; Dmitry Pitushkin; Andrey Vernigora; Elena Rasskazova; Gennady M Butov; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2020-07-24       Impact factor: 2.823

2.  2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity.

Authors:  Juan Martín-López; Sandra Codony; Clara Bartra; Christophe Morisseau; María Isabel Loza; Coral Sanfeliu; Bruce D Hammock; José Brea; Santiago Vázquez
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-17

3.  From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis.

Authors:  Sandra Codony; Carla Calvó-Tusell; Elena Valverde; Sílvia Osuna; Christophe Morisseau; M Isabel Loza; José Brea; Concepción Pérez; María Isabel Rodríguez-Franco; Javier Pizarro-Delgado; Rubén Corpas; Christian Griñán-Ferré; Mercè Pallàs; Coral Sanfeliu; Manuel Vázquez-Carrera; Bruce D Hammock; Ferran Feixas; Santiago Vázquez
Journal:  J Med Chem       Date:  2021-05-04       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.